Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechFRA:F7Y -2.80%60 Earnings Yield (Joel Greenblatt) % is 11.60% as of Dec. 2025, which is 22% below its 10-year median of 14.91. GuruFocus rates FRA:F7Y with a GF Score™ of 60/100 and a GF Value™ of €1.44. The stock has 3 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Gaush Meditech ranks better than 94.1% on this metric.
Gaush Meditech's Enterprise Value for the quarter that ended in Dec. 2025 was €133.0 Mil.
Gaush Meditech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €12.4 Mil. Gaush Meditech's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 11.60%.
The historical rank and industry rank for Gaush Meditech's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:F7Y'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7.75 Med: 14.91 Max: 27.71
Current: 15.17
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Gaush Meditech was 27.71%. The lowest was -7.75%. And the median was 14.91%.
FRA:F7Y's Earnings Yield (Joel Greenblatt) % is ranked better than 94.1% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: 0.96
vs FRA:F7Y: 15.17
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Gaush Meditech's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Gaush Meditech Earnings Yield (Joel Greenblatt) % Related Terms
Gaush Meditech Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gaush Meditech's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Gaush Meditechs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 11.60% mean?
Gaush Meditech (FRA:F7Y) has a Earnings Yield (Joel Greenblatt) % of 11.60% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gaush Meditech and its competitors. This is 22% below median its historical median of 14.91. According to the industry distribution chart, Gaush Meditech ranks #50 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 5.9%.
Is Gaush Meditech's Earnings Yield (Joel Greenblatt) % too high?
Gaush Meditech's current Earnings Yield (Joel Greenblatt) % of 11.60% is 22% below median its 10-year median of 14.91. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.96. Gaush Meditech's value of 11.60% is 1108.3% above this industry median. Based on the distribution chart, Gaush Meditech ranks #50 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gaush Meditech has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #50 out of 847 companies for Earnings Yield (Joel Greenblatt) %. This places Gaush Meditech in the top 6% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 0.96. Gaush Meditech's value of 11.60% is 1108.3% above this benchmark. While the company's 10-year median is 14.91 vs. the industry median of 0.96, Gaush Meditech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.96, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current Earnings Yield (Joel Greenblatt) % of 11.60% is 1108.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current Earnings Yield (Joel Greenblatt) % is 11.60%, which is 22% below median its own 10-year median of 14.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Gaush Meditech (FRA:F7Y) has a current Earnings Yield (Joel Greenblatt) % of 11.60%. The stock's GF Value™ is €1.44, compared to a current price of €0.49 — trading 66.3% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 11.60%, which is 22% below median its 10-year median of 14.91 and 1108.3% above the Medical Devices & Instruments industry median of 0.96. Gaush Meditech's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current Earnings Yield (Joel Greenblatt) % is 11.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of €0.49 is trading 66.3% below its estimated GF Value™ of €1.44.
Key valuation signals for FRA:F7Y:
Earnings Yield (Joel Greenblatt) %: 11.60% (22% below median its 10-year median of 14.91)
GF Value™: €1.44 vs. price of €0.49 (66.3% below fair value)
Industry Position: 1108.3% above the Medical Devices & Instruments median (#50 of 847)
No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
60GF Score
Get the complete analysis for FRA:F7Y
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F7Y has been successfully added to your 
